{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:02:38Z","timestamp":1793628158251,"version":"4.5.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016359"],"award-info":[{"award-number":["P30 CA016359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00277-021-04734-2","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:03:16Z","timestamp":1641254596000},"page":"557-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes"],"prefix":"10.1007","volume":"101","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Seet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Raymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sriraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kopytek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"7","key":"4734_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441. https:\/\/doi.org\/10.1038\/bcj.2016.50","journal-title":"Blood Cancer J"},{"issue":"5","key":"4734_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","volume":"8","author":"DP Steensma","year":"2018","unstructured":"Steensma DP (2018) Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J 8(5):47","journal-title":"Blood Cancer J"},{"issue":"1","key":"4734_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajh.24253","volume":"91","author":"N Gangat","year":"2016","unstructured":"Gangat N, Patnaik MM, Tefferi A (2016) Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol 91(1):76\u201389","journal-title":"Am J Hematol"},{"issue":"6","key":"4734_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, Carew JS, Nawrocki ST, Persky D, Anwer F (2018) Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review. Blood Rev 32(6):480\u2013489","journal-title":"Blood Rev"},{"issue":"17","key":"4734_CR5","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1121629109","volume":"109","author":"B Edris","year":"2012","unstructured":"Edris B, Weiskopf K, Volkmer AK, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 109(17):6656\u20136661","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4734_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R (2012) The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24(2):225\u2013232","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"4734_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1084\/jem.193.7.855","volume":"193","author":"PA Oldenborg","year":"2001","unstructured":"Oldenborg PA, Gresham HD, Lindberg FP (2001) CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 193(7):855\u2013862","journal-title":"J Exp Med"},{"issue":"27","key":"4734_CR8","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL (2013) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110(27):11103\u201311108. https:\/\/doi.org\/10.1073\/pnas.1305569110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"4734_CR9","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua M-S, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorna M, Raveh T, Tseng D, Jaiswal S, Enger P\u00d8, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NNH, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109(17):6662\u20136667. https:\/\/doi.org\/10.1073\/pnas.1121623109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5473","key":"4734_CR10","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP (2000) Role of CD47 as a marker of self on red blood cells. Science 288(5473):2051\u20132054","journal-title":"Science"},{"issue":"6","key":"4734_CR11","first-page":"2901","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Lu S, Xu Y, Qiu C, Jin C, Wang Y, Liu Z, Kong B (2017) Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am J Transl Res 9(6):2901\u20132910","journal-title":"Am J Transl Res"},{"issue":"8","key":"4734_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.leukres.2013.04.008","volume":"37","author":"H Jiang","year":"2013","unstructured":"Jiang H, Fu R, Wang H, Li L, Liu H, Shao Z (2013) CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome. Leuk Res 37(8):907\u2013910. https:\/\/doi.org\/10.1016\/j.leukres.2013.04.008","journal-title":"Leuk Res"},{"key":"4734_CR13","doi-asserted-by":"crossref","unstructured":"Zheng B, Wong P, Yang W, Narla R, Burgess M, Escoubet L, Raymon H, Hariharan K, Boylan J, Hege K (2017) CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is associated with an increase in M1-polarized macrophages. Cancer Res 77 (13 Suppl):Abstract 2009","DOI":"10.1158\/1538-7445.AM2017-2009"},{"key":"4734_CR14","doi-asserted-by":"publisher","unstructured":"Narla RK, Modi H, Wong L, Abassian M, Bauer D, Desai P, Gaffney B, Jackson P, Leisten J, Liu J, Lopez-Girona A, Romero M, Yang W, Eckelman BP, Deveraux Q, Phillips L, Raymon HK, Escoubet L, Boylan J, Hariharan K (2017) Abstract 4694: the humanized anti-CD47 monoclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Res 77 (13 Suppl):Abstract 4694. doi:https:\/\/doi.org\/10.1158\/1538-7445.AM2017-4694","DOI":"10.1158\/1538-7445.AM2017-4694"},{"issue":"8","key":"4734_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1553","volume":"27","author":"AF Labrijn","year":"2009","unstructured":"Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27(8):767\u2013771. https:\/\/doi.org\/10.1038\/nbt.1553","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4734_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.4049\/jimmunol.164.4.1925","volume":"164","author":"MP Reddy","year":"2000","unstructured":"Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A (2000) Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 164(4):1925\u20131933. https:\/\/doi.org\/10.4049\/jimmunol.164.4.1925","journal-title":"J Immunol"},{"key":"4734_CR17","doi-asserted-by":"publisher","unstructured":"Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K (2021) Modulation of CD47-SIRPalpha innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother (in press). https:\/\/doi.org\/10.1007\/s00262-021-03010-6","DOI":"10.1007\/s00262-021-03010-6"},{"key":"4734_CR18","unstructured":"Guide for the Care and Use of Laboratory Animals (2011). 8 edn. The National Academies Press, Washington, DC"},{"key":"4734_CR19","doi-asserted-by":"publisher","unstructured":"Zeidan AM, DeAngelo DJ, Palmer JM, Seet CS, Tallman MS, Wei X, Li YF, Hock N, Burgess MR, Hege K, Stock W (2019) A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory (R\/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results. Blood 134 (Supplement_1):1320\u20131320. https:\/\/doi.org\/10.1182\/blood-2019-125363","DOI":"10.1182\/blood-2019-125363"},{"issue":"2","key":"4734_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC (2008) Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol 26(2):190\u2013195. https:\/\/doi.org\/10.1200\/JCO.2007.12.7712","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"4734_CR21","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/blood-2019-125310","volume":"134","author":"P Abrisqueta","year":"2019","unstructured":"Abrisqueta P, Sancho J-M, Cordoba R, Persky D, Andreadis C, Huntington S, Carpio C, Giles D, Wei X, Li Y, Zuraek M, Burgess M, Hege K, Martin A (2019) Anti-CD47 antibody, CC-90002, in combination with rituximab in subjects with relapsed and\/or refractory non-Hodgkin lymphoma (R\/R NHL). Blood 134(Supplement 1):4089","journal-title":"Blood"},{"key":"4734_CR22","doi-asserted-by":"publisher","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis SoRCTO, Reporting Standards for Therapeutic Trials in Acute Myeloid L (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (24):4642-4649. https:\/\/doi.org\/10.1200\/JCO.2003.04.036","DOI":"10.1200\/JCO.2003.04.036"},{"issue":"2","key":"4734_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419\u2013425. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"issue":"18","key":"4734_CR24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med 379(18):1711\u20131721. https:\/\/doi.org\/10.1056\/NEJMoa1807315","journal-title":"N Engl J Med"},{"issue":"7","key":"4734_CR25","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/trf.15397","volume":"59","author":"CK Brierley","year":"2019","unstructured":"Brierley CK, Staves J, Roberts C, Johnson H, Vyas P, Goodnough LT, Murphy MF (2019) The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. Transfusion 59(7):2248\u20132254. https:\/\/doi.org\/10.1111\/trf.15397","journal-title":"Transfusion"},{"issue":"7","key":"4734_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, Rutgeerts P, (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 348(7):601\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa020888","journal-title":"N Engl J Med"},{"issue":"9","key":"4734_CR27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther 28(9):1122\u20131126. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03828.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"4734_CR28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739\u20131745. https:\/\/doi.org\/10.1136\/ard.2008.092833","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4734_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/jco.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O\u2019Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK (2019) First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 37(12):946\u2013953. https:\/\/doi.org\/10.1200\/jco.18.02018","journal-title":"J Clin Oncol"},{"key":"4734_CR30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"MP Chao","year":"2019","unstructured":"Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R (2019) Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol 9:1380. https:\/\/doi.org\/10.3389\/fonc.2019.01380","journal-title":"Front Oncol"},{"key":"4734_CR31","doi-asserted-by":"publisher","unstructured":"Sallman DA, Donnellan WB, Asch AS, Lee DJ, Al Malki M, Marcucci G, Pollyea DA, Kambhampati S, Komrokji RS, Van Elk J, Lin M, Agoram B, Chen JY, Volkmer J-P, Takimoto CHM, Chao M, Vyas P (2019) The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: initial phase 1b results. J Clin Oncol 37 (15_suppl):Abstract 7009. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7009","DOI":"10.1200\/JCO.2019.37.15_suppl.7009"},{"key":"4734_CR32","doi-asserted-by":"publisher","unstructured":"Sallman DA, Al Malki M, Asch AS, Lee DJ, Kambhampati S, Donnellan WB, Bradley TJ, Vyas P, Jeyakumar D, Marcucci G, Komrokji RS, Van Elk J, Lin M, Maute R, Volkmer J-P, Takimoto CHM, Chao M, Daver NG (2020) Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J Clin Oncol 38 (15_suppl):Abstract 7507. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507"},{"issue":"2","key":"4734_CR33","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.4238\/2015.May.25.15","volume":"14","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yin C, Feng L, Wang C, Sheng G (2015) Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. Genet Mol Res 14(2):5630\u20135641. https:\/\/doi.org\/10.4238\/2015.May.25.15","journal-title":"Genet Mol Res"},{"issue":"10","key":"4734_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21(10):1209\u20131215. https:\/\/doi.org\/10.1038\/nm.3931","journal-title":"Nat Med"},{"issue":"9","key":"4734_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG (2019) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470\u20131481. https:\/\/doi.org\/10.1002\/cncr.31896","journal-title":"Cancer"},{"issue":"1","key":"4734_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imm.12290","volume":"143","author":"LS Kwong","year":"2014","unstructured":"Kwong LS, Brown MH, Barclay AN, Hatherley D (2014) Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity\u2013implications for engraftment of human cells. Immunology 143(1):61\u201367. https:\/\/doi.org\/10.1111\/imm.12290","journal-title":"Immunology"},{"issue":"7","key":"4734_CR37","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","volume":"189","author":"MB Overdijk","year":"2012","unstructured":"Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW (2012) Crosstalk between human IgG isotypes and murine effector cells. J Immunol 189(7):3430\u20133438. https:\/\/doi.org\/10.4049\/jimmunol.1200356","journal-title":"J Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04734-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:06:18Z","timestamp":1643857578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04734-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4734"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04734-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was reviewed and approved by each site\u2019s Institutional Review Board prior to initiation of the study. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and in adherence to Good Clinical Practice as described in the International Council for Harmonisation E6 guidance. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A.M.Z. received research funding from Celgene (a Bristol Myers Squibb Company), AbbVie, Astex, Pfizer, Medimmune\/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; served as a consultant for and received honoraria from AbbVie, Otsuka, Pfizer, Celgene (a Bristol Myers Squibb Company), Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, BeyondSpring, Trovagene, Takeda, Ionis, Tyme, Amgen, Janssen, Gilead, Kura, Aprea, and Epizyme; and received travel support for meetings from Pfizer, Novartis, and Trovagene. D.J.D. received research funding from AbbVie, Glycomimetics, Novartis, and Blueprint Pharmaceuticals and served as a consultant for and received honoraria from Amgen, Autolus, Blueprint, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda. M.S.T. received research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, and Biosight; served as a consultant for AbbVie, BiolineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, and Jazz Pharma; and holds royalties with UpToDate. M.B. holds patents and royalties with Celgene (a Bristol Myers Squibb Company) and University of California and is an employee and equity owner with Bristol Myers Squibb. K.H. is an employee and equity owner with Bristol Myers Squibb and served as a member of advisory board for Arcus Biosciences, Mersana Therapeutics, and Society for Immunotherapy of Cancer. W.S. received research funding from AbbVie, Amgen, Jazz, Pfizer, and Xencor; received honoraria from AbbVie, Amgen, and Pfizer; and served as a consultant for AbbVie, Amgen, Astella, GlaxoSmithKline, Kite, Jazz, Morphosys, and Pfizer. H. Raymon was an employee of and is an equity owner with Bristol Myers Squibb. X.W., P.S., and S.K. are employees of and equity owners with Bristol Myers Squibb. J.P., J.P.B. and C.S.S. declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}